Amino-piperidine derivatives
AssigneeHoffmann-La Roche Inc.
InventorsDaniela Alberati-Giani, Simona Maria Ceccarelli, Emmanuel Pinard, Henri Stalder
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of the general formula 1 wherein X and Y are each independently selected from —CH2— or —O—, with the proviso that X and Y are not simultaneously —O—; A is —S(O)2— or —C(O)—; and R1, R2, R3, and R4 are as defined in the specification. The compounds are GlyT-1 inhibitors and are useful for the treatment of psychoses, pain, dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
Claims50
A compound of formula
- 21
- wherein
- R1 is lower alkyl, —(CH2)n-aryl, unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, lower alkoxy, —OCF3, halogen, —NR′R″ and trifluoromethyl, or is heteroaryl;
- R2 is lower alkyl —(CH2)n-aryl, unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, trifluoromethyl, nitro, cyano, —NR′R″, hydroxy, and a heteroaryl group, or is heteroaryl, unsubstituted or substituted by one or two substituents selected from the group consisting of lower alkyl and halogen;
- R3 is heteroaryl or is aryl, unsubstituted or substituted by halogen or lower alkyl;
- R4 is hydrogen or hydroxy;
- A is —S(O)2— or —C(O)—;
- X and Y are each independently selected from the group consisting of —CH2— and —O—, with the proviso that X and Y are not simultaneously —O—;
- R′ and R″ are each independently selected from the group consisting of hydrogen, lower alkyl and —C(O)-lower alkyl;
- n is 0, 1 or 2;
- or a pharmaceutically acceptable acid addition salt thereof.
A compound according to claim 26, wherein A is —C(O)—.
Dependencies are inferred from the claim text.